Key factors
sym | EARS |
exch | US |
MCap | 39.18M |
Beta | 1.404 |
EPS | -1.48 |
Div date | 0000-00-00 |
Yesterday
sym | EARS |
exch | US |
close | 2.39 |
50 Day MA | 3.245 |
200 Day MA | 3.405 |
Target Price | 14.95 |
Market Cap Mln | 39.18 |
Share statistics
Shares Outstanding | 12.86M |
Shares Float | 12.13M |
Percent Institutions | 5.585 |
PercentInsiders | 5.445 |
SharesShort | 150.09K |
Short Ratio | 0.08 |
Shares Short Prior Month | 66514 |
Short Percent | 1.240 |
Income
Revenue TTM | 174.47K |
Revenue Per Share TTM | 0.029 |
Gross Profit TTM | 174.47K |
Diluted Eps TTM | -1.48 |
earning
Operating Margin TTM | -30.2 |
Earnings Share | -1.48 |
Dividend
Dividend Date | 2019-05-01 |
Last Split Date | 2019-05-01 |
Last Split Factor | 1:20 |
business
Enterprise Value Ebitda | 0.120 |
Enterprise Value Revenue | 150.57 |
Book Value /share | 1.469 |
Price Book MRQ | 2.081 |
Price Sales TTM | 93.49 |
ReturnOnAssetsTTM | -0.21 |
ReturnOnEquityTTM | -0.71 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Pharmaceuticals |
Gic Sector | Health Care |
Gic Sub Industry | Pharmaceuticals |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | BMG0360L1000 |
Code | EARS |
CUSIP | G07025201 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2021-11-14 |
is Delisted | 1 |
Delisted Date | 2021-09-24 |
Home Category | ADR |
info
Fiscal Year End | December |
Full Time Employees | 8.0 |
IPODate | 2014-08-06 |
International Domestic | Domestic |
MostRecent Quarter | 2020-12-31 |
Contact
Name | Auris Medical Holding Ltd |
Address | Clarendon House, Hamilton, Bermuda, HM 11 |
Country Name | USA |
Phone | 441 295 5950 |
Web URL | www.aurismedical.com |
Auris Medical Holding Ltd., a clinical-stage biopharmaceutical company, developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy, and CNS disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; AM-201, which has completed Phase 1b clinical trial for the prevention of antipsychotic induced weight gain and drowsiness; and AM-301, a drug-free nasal spray for protection against airborne viruses and allergens, as well as AM-102 for the tinnitus treatment. The company has a collaboration and license agreement with INSERM; and Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. Auris Medical Holding Ltd. was founded in 1998 and is headquartered in Hamilton, Bermuda.